Infrared Light and Mitochondria: Latest Research on Photobiomodulation Mechanisms and Clinical Applications

Infrared light (especially near-infrared and far-infrared) interacting with mitochondria is a major research focus in biomedical photonics. As a non-invasive, non-pharmacological physical intervention, it shows substantial therapeutic potential across multiple disease models, with mechanisms largely centered on mitochondria. This post summarizes recent advances in mechanisms, disease applications, and future challenges.

1. Core Mechanisms: How Infrared Light "Talks" to Mitochondria

The biological effects of infrared light (particularly the 600–1350 nm band with the best tissue penetration) are mainly achieved through photobiomodulation (PBM), with mitochondria as the core target:

• Photons are absorbed by cytochrome c oxidase (CCO) in mitochondria
• This activates the electron transport chain, increasing ATP synthesis
• Moderate ROS production acts as signaling molecules, modulating oxidative stress balance
• Nitric oxide (NO) release improves vasodilation, blood flow, and tissue oxygenation

Recent research also reveals deeper mechanisms involving regulation of mitochondrial dynamics (the fusion–fission balance), which is critical for cellular health.

| Band | Mechanism (mitochondrial dynamics) | Main effect | Model/evidence | | :--- | :--- | :--- | :--- | | Near-infrared (850 nm) | Upregulates fusion proteins MFN1/2, promoting fusion | Enhanced OXPHOS and fatty acid oxidation; drives macrophages toward anti-inflammatory M2; promotes wound healing | Macrophage polarization models, mouse wound model (healing rate >95%) | | Red light (625 nm) | Upregulates fission protein DRP1, promoting fission | Enhanced glycolysis; drives pro-inflammatory M1 polarization; delays inflammation (healing rate <55% at same dose) | Macrophage polarization models, mouse wound model | | Far-infrared | Stabilizes dynamics, upregulates OPA1 | Restores mitochondrial membrane potential, reduces oxidative stress; neuroprotection | Rat ischemic stroke (MCAO), oxygen-glucose deprivation neurons |

> Key insight: regulation of mitochondrial dynamics is wavelength-dependent. Different wavelengths can even produce opposite effects (red light promotes fission; near-infrared promotes fusion), so clinical parameters must be carefully selected.

2. Frontier Research and Applications

2.1 Mitochondria as Drug Carriers

A team at Peking University School of Pharmaceutical Sciences (Qi Xianrong) engineered mitochondria themselves as drug carriers, transported via the cell's natural tunneling nanotube (TNT) communication network:

• Oxidative stress signals promote TNT formation; mitochondria transfer bidirectionally between cells via TNTs
• CRISPR/siRNA knockdown of the PINK1 gene inhibits mitophagy, triggering compensatory responses (more TNTs, enhanced OXPHOS, increased mitochondrial motility)
• Mitochondria loaded with drugs such as the photosensitizer IR780 act as a self-driven delivery system with good biocompatibility, capable of crossing physiological barriers and achieving deep tumor penetration — promising for glioma and other refractory tumors

This study is the first to use an organelle as a delivery vehicle, revealing a novel physiological role of mitochondria in intercellular communication.

2.2 Neurological Diseases

• Acquired brain injury (stroke, TBI): Near-infrared PBM enhances mitochondrial function, reduces oxidative stress and neuroinflammation, and promotes neural repair and synaptogenesis. Clinical studies show improved cognition in TBI patients and reduced PTSD symptoms. Far-infrared upregulates OPA1, stabilizing mitochondrial dynamics and significantly reducing infarct volume and cerebral edema after ischemic stroke.
• Neurodegenerative disease: Animal experiments show transcranial PBM protects dopaminergic neurons in Parkinson's disease models, likely by improving mitochondrial function and reducing alpha-synuclein aggregation.

2.3 Cardiovascular Rehabilitation

• Reduced infarct size: Trans-sternal 810 nm near-infrared irradiation reduced infarct area by over 60% in preclinical studies.
• Improved cardiac function: Increased ATP, reduced oxidative stress markers (MDA), and modulated inflammatory cytokines (lower IL-6 and TNF-alpha, higher IL-10).
• New devices such as trans-sternal irradiation devices and programmable transcranial helmets support precise non-invasive treatment.

2.4 Wound Healing and Skin Repair

• Near-infrared light promotes mitochondrial fusion and M2 macrophage polarization, accelerating tissue repair and angiogenesis.
• 850 nm near-infrared (50 J/cm²) for 12 days achieved mouse wound healing rates above 95%.
• Infrared light also promotes fibroblast proliferation and collagen deposition, accelerating wound closure.

2.5 Oncology Applications

• Precision photothermal therapy (PTT): Jinling Institute of Technology researchers used TPP-modified gold nanorods to target mitochondria; under near-infrared irradiation they produced localized heat effects and captured, for the first time in living cells, the two-stage outer-membrane rearrangement of transient fusion followed by fission. By tuning thermal stress dose, they achieved panoptosis-based precise control over cell death mode (apoptosis, necroptosis, pyroptosis), addressing the non-specific damage of conventional PTT.
• Mitochondria-mediated deep delivery: as above, mitochondria and TNT networks carrying IR780 enable efficient deep tumor penetration, with near-infrared-controllable TNT dynamics.

3. Clinical Translation and Future Outlook

Historical timeline: low-intensity red light for hair growth discovered in Hungary (1960s); NASA research on red light accelerating wound healing (2000s); CCO identified as key photoreceptor and mitochondrial dynamics mechanisms clarified (2020s); 2025 — US FDA approved red-light devices for dry age-related macular degeneration, and oral red-light therapy included in guidelines to prevent oral mucositis from cancer treatment.

Current Challenges and Future Directions

1. Dose optimization and individualization: PBM exhibits a biphasic dose response (low doses stimulate, high doses inhibit); optimal wavelength, dose, power, duration, and frequency vary by tissue, disease state, and individual. 2. Lack of large-scale clinical evidence: most studies remain preclinical or small-scale; rigorous large randomized controlled trials are urgently needed, especially in cardiovascular and neurological diseases. 3. Complete mechanism elucidation: responses persist even with mitochondrial inhibitors, suggesting non-CCO mechanisms; roles of endogenous biophotons and intercellular mitochondrial communication merit exploration. 4. Device standardization: device development currently relies on trial and error; standardization and clinical guidelines are needed. 5. Combination therapies: combining infrared phototherapy with chemotherapy, immunotherapy, PTT + PDT, or immune checkpoint inhibitors may yield synergistic effects.

Conclusion

Research on infrared light and mitochondria has progressed from phenomenon observation to mechanism elucidation, demonstrating encouraging therapeutic potential across disease models. The core lies in precisely regulating mitochondrial function through photobiomodulation, influencing cellular metabolism, immune polarization, and cell fate. Recent breakthroughs include differential wavelength-dependent regulation of mitochondrial dynamics (red light promotes fission; near-infrared promotes fusion) and the novel concept of mitochondria as drug carriers and delivery networks. While dose optimization, standardization, and large-scale validation remain before widespread clinical adoption, this field opens a promising new window for future medicine — particularly in neuroprotection, cardiovascular rehabilitation, and refractory tumor therapy.